STAAR Surgical Company (NASDAQ:STAA) has unveiled its preliminary net sales for Q1 2024, showcasing a record-setting performance in U.S. ICL sales and total net sales surpassing $77 million.

This announcement precedes the in-depth financial discussions scheduled for the quarterly earnings call on May 8, 2024, and underscores STAAR Surgical's robust growth momentum.

The company witnessed a remarkable 20% sequential increase in U.S. ICL sales, reaching $5 million, alongside an 11% annual growth in EMEA ICL sales.

Furthermore, STAAR Surgical anticipates that its annual net sales for 2024 might exceed the forecasted range of $335 million to $340 million.

These figures, while preliminary, signify the potential financial adjustments and will be elaborated upon in the forthcoming detailed quarterly report.

As of March 29, 2024, STAAR reported a solid financial position with approximately $248 million in cash, cash equivalents, and investments, showing a notable increase from $232.4 million at the end of the previous quarter in December 2023.